Abstract
There is now clear evidence that the prevalence of co-morbidity among older cancer patients is high and that older patients (with comorbidity) are often treated less aggressively, which seems to have a negative influence on survival. However, would outcomes really improve if more patients were treated, according to the guidelines that were developed on the basis of results in groups of younger patients without co-morbidity? Would more complications occur in older patients with co-morbidity? If that is the case, is it possible to develop special treatment regimens for older cancer patients with co-morbidity and adapt the guidelines? It remains relevant to study the influence of age and co-morbidity on toxicity from treatment, quality of life and prognosis in unselected groups of patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
